000 01283 a2200349 4500
005 20250516025930.0
264 0 _c20110901
008 201109s 0 0 eng d
022 _a1744-7631
024 7 _a10.1517/14728222.2011.561319
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSarra, Massimiliano
245 0 0 _aTargeting interleukin-21 in inflammatory diseases.
_h[electronic resource]
260 _bExpert opinion on therapeutic targets
_cJun 2011
300 _a695-702 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAnimals
650 0 4 _aAnti-Inflammatory Agents
_xpharmacology
650 0 4 _aB-Lymphocytes
_ximmunology
650 0 4 _aDrug Delivery Systems
650 0 4 _aHumans
650 0 4 _aImmune System Diseases
_xdrug therapy
650 0 4 _aInflammation
_xdrug therapy
650 0 4 _aInterleukins
_xantagonists & inhibitors
650 0 4 _aT-Lymphocytes
_ximmunology
650 0 4 _aInterleukin-21
700 1 _aFranzè, Eleonora
700 1 _aPallone, Francesco
700 1 _aMonteleone, Giovanni
773 0 _tExpert opinion on therapeutic targets
_gvol. 15
_gno. 6
_gp. 695-702
856 4 0 _uhttps://doi.org/10.1517/14728222.2011.561319
_zAvailable from publisher's website
999 _c20664108
_d20664108